stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Gross margin
TG Therapeutics, Inc.'s gross margin over the twelve months to 30 June 2026 was 82.4%, down 1.3 percentage points from fiscal 2025 (83.7%). Over the past ten years it has ranged from 83.7% (fiscal 2025) to 100.0% (fiscal 2020) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 83.7% | (4.64) |
| FY2024 | 88.3% | (5.65) |
| FY2023 | 94.0% | 3.47 |
| FY2022 | 90.5% | 2.29 |
| FY2021 | 88.2% | (11.81) |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 82.9% | (0.79) |
| Mar 2026 | 83.7% | 3.46 |
| Dec 2025 | 80.2% | (2.44) |
| Sep 2025 | 82.6% | (3.95) |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. compare | 100.0% |
| IBRX ImmunityBio, Inc. compare | 99.3% |
| KRYS Krystal Biotech, Inc. compare | 94.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| TGTX TG Therapeutics, Inc. | 82.4% |
| TWST Twist Bioscience Corporation compare | 52.0% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement